EpiDisease S.L. is an epigenetics biotechnology company founded in 2014 that develops and commercializes proprietary in vitro diagnostic (IVD) products for human diseases, focusing on epigenetic biomarkers. Their mission is to offer innovative diagnostic tools for the early and accurate diagnosis and prognosis of complex diseases and to identify molecular targets for epigenetic therapies. EpiDisease has expertise in DNA methylation, histone modifications, and miRNA analysis, critical for understanding gene expression regulation. The company originated as a spin-off from the Spanish National Institute of Health Carlos III’s Centre for Biomedical Network Research (CIBER) and the Biomedical Research Institute INCLIVA, in collaboration with the University of Valencia.

Recognized as an innovative company by the Spanish Ministry of Economy, EpiDisease holds certifications as a Clinical Diagnostic Center in Genetics and Microbiology. The company is ISO 9001:2015 certified for genetic and epigenetic analysis, with plans to achieve ISO 13485 and ISO 15189 certifications for medical device manufacturing and laboratory competence by late 2023.

EpiDisease’s product pipeline includes technologies based on epigenetic and proteomic biomarkers, with 3 granted patent families in various countries. Through technology transfer agreements. Their main research focus areas are adolescent idiopathic scoliosis, sepsis, and aging, through the exploration of epigenetic basis of these diseases.